myocardial bridging may be highly overlooked in classical coronary angiography. Additionally myocardial bridging on coronary arteries detected on MSCT Angiography should strictly be sought, reported and also identified with its length, compression and luminal narrowing. Those subjects should be followed with the restriction from extremely strenuous exercise rather than mildly regular exercise. Beta blocking drugs may be the best options of therapy in order to reduce the myocardial oxygen demand and work load. Myocardial bridging may not be innocent due to its potential to induce ischemia and LV dysfunction especially in young subjects.
Purpose: To assess whether single dose oral ivabradine referred for CCTA is safe and can significantly decrease the heart rate as compared to IV (intravenous) metoprolol in patients who were receiving calcium channel blocker (CCB) therapy. Methods: One-hundred-twenty patients who were under CCB therapy referred for CCTA were randomized to premedication with single dose ivabradine 15 mg or IV metoprolol 5-10 mg. Hearth rate (HR) were assessed at admission (HR0) and during CTCA scan (HR1) for all patients. Blood pressure (BP) were measured before the medication (BP0) and immediately before CCTA scan (BP1). Results: Although the HR of the groups were not significantly different before the medication (HRIv0¼80 AE 7bpm vs. HRb0¼81 AE 7bpm; p¼0,42), Ivabradine administration significantly reduced HR during CCTA when compared to metoprolol (HRIv1¼62 AE 7 bpm vs. HRb1¼66 AE 6 bpm; p¼0,001). Decreases in HR were for Ivabradine (18AE6 bpm) is significantly higher than for metoprolol (15 AE 4 bpm) (p¼0,003) without relevant side effects. Ivabradine showed no significant effect on both systolic BP or the diastolic BP, (SiBPIv0: 139AE10, SiBPIv1: 138AE10, p¼0.260; DiBPIv0: 81 AE7 DiBPIv1: 81AE6 p¼0.59. Metoprolol group demonstrated statistically significant reduction in both SBP and DBP (SiBPb0:136 AE11, SiBPb1 130AE11, p<0.001; DiBPb0: 81AE6, DiBPb1: 78 AE 6, p<0.001). Conclusıon: Ivabradine is safe and significantly effective in decreasing the HR when compared to IV metoprolol in the patients who were under CCB therapy.
PP-008
The Pulmonary hypertension is associated with different disease groups and has high mortality risk. Eisenmenger syndrome, connective tissue disease and idiopathic form cause pulmonary arterial hypertension (PAH). Rheumatismal mitral stenosis is the leading cause of pulmonary venous hypertension (PVHT). Although it is very good known that these disease cause right heart failure there are no study to compare the degree of right ventricular alteration in these patient groups. We aimed to compare the right ventricle functions between PAH and PVHT with echocardiography and to compare ADMA levels which demonstrate endothelial dysfunction patients in group I and group II had higher ADMA levels than control subjects. The levels of ADMA were not different between patients with PAH and patients with PVHT.
RA area, RA major and minor dimensions, RVEDV, RVESV, systolic PAB, TV systolic tissue Doppler velocity, RV wall thickness, RVOT proximal and distal diameters were significantly higher in group I patients with PAH than in group II patients with PVHT. TV systol time, TV ejection time were similar between groups. RVMPI and RVAC were higher in group II patients than in group I.
Group II patients divided to subgroups a; higher PVR and b; lower PVR in patients with mitral stenosis according to Abbas Formula. RVMPI, RVFAC, TV systolic tissue doppler velocity, ADMA levels were different between groups. Group IIa patients had higher ADMA levels, MPI, TV systolic tissue doppler velocity and lower RVAFC than group IIb patients. Dıscussıon: PAH causes increased risk of mortality due to right heart failure. Right heart failure may occur in patients with mitral stenosis in long term. Our study demonstrated that PAH patients had worse right heart functions than PVHT patients as expected. In patients with high PVR due to mitral stenosis if the operation is delayed the prognosis will be the worse as shown in our study that group II patients with high PVR has worse right heart functions than others. The other internetini finding of our study is the similar ADMA levels between PAH and PVHT patients. In literatüre there is no similar study. We can assume that ADMA level in pulmonary HT may demonstrate the presence of pulmonary HT not the magnitude.
